Abivax SA American Depositary Shares
ABVXStock
$137.77+1229.63%52W
Market Cap$11.97B
P/E—
Div yield—
Beta0.38
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)5.73%
Price vs S&P 500 (4W)38.38%
VGM Score75.38
Market Capitalization$11.97B
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABVXAbivax SA American Depositary Shares | — | — | B | $137.77 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Abivax is a French clinical-stage biotechnology company developing therapeutics designed to regulate immune response in chronic inflammatory diseases. The company's lead candidate, obefazimod, is in Phase 3 development for moderately to severely active ulcerative colitis. Abivax focuses on inflammatory bowel disease, including both ulcerative colitis and Crohn's disease.